ASH 2022 UK NCRI AML19 Trial: FLAG-Ida With Gemtuzumab Ozogamicin Improves EFS in Younger Patients With Newly Diagnosed AML and Shows an OS Benefit in NPM1- & FLT3-Mutated Subgroups

89 views
December 28, 2022
Comments 0
Login to view comments. Click here to Login